Summary & Overview
HCPCS C9507: High-Titer COVID-19 Convalescent Plasma, Per Unit
HCPCS Level II code C9507 denotes a single unit of high-titer COVID-19 convalescent plasma, a blood-derived biologic used for transfusion to patients with COVID-19. This code matters nationally as it standardizes billing for a specific therapeutic plasma product used in acute care and transfusion settings, enabling consistent claims processing and monitoring of utilization for pandemic-related treatments. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what C9507 represents, payer coverage patterns, and the clinical context for use of convalescent plasma. The publication outlines benchmarks and reimbursement context where available, summarizes relevant policy updates affecting coverage and billing, and highlights common billing considerations for hospital and transfusion center service lines. Information on associated modifiers, taxonomies, ICD-10 diagnoses, and related codes is noted where available; when not provided, the report states data gaps. This national-level briefing is intended for billing managers, revenue cycle staff, and policy analysts seeking a practical summary of the code, its clinical application, and payer considerations for high-titer COVID-19 convalescent plasma.
Billing Code Overview
HCPCS Level II code C9507 represents Plasma, high titer COVID-19 convalescent, each unit. This code is used for the billing of individual units of high-titer convalescent plasma collected from individuals who have recovered from COVID-19 and meet criteria for high antibody levels.
-
Service type: Therapeutic blood product transfusion / biologic therapy
-
Typical site of service: Hospital inpatient and outpatient settings, emergency departments, and transfusion centers where blood products are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult hospitalized with severe or high-risk COVID-19 who meets criteria for high-titer convalescent plasma therapy. The patient may have progressive hypoxemia, risk factors for poor outcomes (for example, advanced age, immunocompromise, or multiple comorbidities), and symptom onset within the timeframe where passive antibody therapy is considered potentially beneficial. The clinical workflow begins with confirmation of the indication by the treating physician (hospitalist, infectious disease specialist, or intensivist), verification of patient consent, and review of transfusion history and compatibility testing by the transfusion service or blood bank. Blood bank staff locate and authorize release of a unit labeled C9507 (Plasma, high titer COVID-19 convalescent, each unit), perform pretransfusion testing (type and screen, crossmatch as required), and ensure appropriate storage and transport. At bedside, nursing prepares the intravenous access, verifies patient identity and transfusion consent, and initiates the transfusion under established transfusion monitoring protocols. Vital signs and infusion tolerance are monitored throughout; any transfusion reaction triggers immediate cessation, evaluation, and documentation. Post-transfusion documentation includes unit lot number, donor high-titer designation, volume infused, start and stop times, and any adverse events. Billing for the plasma unit uses C9507 and may include applicable modifiers to reflect unusual circumstances, split billing, or organizational and clinical responsibilities.
Coding Specifications
| Modifier | Description | When to Use |
|---|